BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Akari Therapeutics Stock (AKTX) Rises After Patent Filing for Novel Cancer Therapy
Akari Therapeutics Stock (AKTX) Rises After Patent Filing for Novel Cancer Therapy
14
3
BTCCSquare news:
Akari Therapeutics' shares surged 6% to $0.80 following the filing of a provisional patent application for its innovative antibody drug conjugate platform. The biotech firm's targeted cancer treatment disrupts alternative splicing—a fundamental cellular process—rather than focusing on single mutations, potentially broadening its therapeutic reach.
The patent application covers Akari's PH1-delivering system, which hijacks cancer cells' protein synthesis mechanisms. Market observers note the stock's rebound contrasts sharply with its 35% decline over the previous quarter, suggesting renewed investor confidence in the company's proprietary technology.
By:
